Xenon Xe 129 hyperpolarized

(Xenoview®)

Xenon Xe 129 hyperpolarized

Drug updated on 9/4/2024

Dosage FormInhalation (oral; 1000 mL)
Drug ClassHyperpolarized contrast agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Xenoview (xenon xe 129 hyperpolarized) is indicated for use with magnetic resonance imaging (MRI) for the evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.
  • This summary is based on the review of three systematic review(s)/meta-analysis(es). 3. [1-3]
  • Xe MRI in Long-COVID patients: 129Xe MRI identified persistent gas exchange and ventilation abnormalities up to one year post-COVID-19 infection, even when other diagnostic tests (pulmonary function tests, chest CT scans) appeared normal or nearly normal.
  • Neuroprotective effects in brain injuries: Xenon showed significant neuroprotective effects in preclinical studies of brain injuries, with effect sizes of 34.1% (95% CI, 24.7-43.6%) and 27.4% (95% CI, 11.5-43.3%), including CPB models, and was significantly more protective than argon.
  • Hyperpolarized gas MRI in Cystic Fibrosis patients: Hyperpolarized gas MRI, including xenon-129, was more sensitive than FEV1 in detecting structural and functional lung abnormalities in CF patients, showing responsiveness to treatments and potential utility in early disease detection and longitudinal monitoring.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.